The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions

The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions

Background The objective of this case study is to pilot a framework of public contributions examining the origins of products from two major European pharmaceutical companies, Novartis and Novo Nordisk, that received approval from the European Medicines Agency (EMA) between January 2014 and May 2024...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Fabian, Ozren Sehic, Claudia Wild
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Pharmaceutical Policy and Practice
Subjects:
Public contributions
Novo Nordisk
Novartis
product origin
public return on public investments (PRoPI)
transparency
Online Access:https://www.tandfonline.com/doi/10.1080/20523211.2025.2534919
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/20523211.2025.2534919

Similar Items